These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 29861018)

  • 1. Randomized, Prospective, Blinded-Enrollment, Head-To-Head Venous Leg Ulcer Healing Trial Comparing Living, Bioengineered Skin Graft Substitute (Apligraf) with Living, Cryopreserved, Human Skin Allograft (TheraSkin).
    Towler MA; Rush EW; Richardson MK; Williams CL
    Clin Podiatr Med Surg; 2018 Jul; 35(3):357-365. PubMed ID: 29861018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A retrospective clinical study of 188 consecutive patients to examine the effectiveness of a biologically active cryopreserved human skin allograft (TheraSkin®) on the treatment of diabetic foot ulcers and venous leg ulcers.
    Landsman AS; Cook J; Cook E; Landsman AR; Garrett P; Yoon J; Kirkwood A; Desman E
    Foot Ankle Spec; 2011 Feb; 4(1):29-41. PubMed ID: 21135263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bilayered bioengineered skin substitute (Apligraf): a review of its use in the treatment of venous leg ulcers and diabetic foot ulcers.
    Curran MP; Plosker GL
    BioDrugs; 2002; 16(6):439-55. PubMed ID: 12463767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a Cryopreserved Split-Thickness Human Skin Allograft-TheraSkin.
    Landsman A; Rosines E; Houck A; Murchison A; Jones A; Qin X; Chen S; Landsman AR
    Adv Skin Wound Care; 2016 Sep; 29(9):399-406. PubMed ID: 27538107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and economic impact of Apligraf for the treatment of nonhealing venous leg ulcers.
    Fivenson D; Scherschun L
    Int J Dermatol; 2003 Dec; 42(12):960-5. PubMed ID: 14636194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective, randomised, controlled, multi-centre comparative effectiveness study of healing using dehydrated human amnion/chorion membrane allograft, bioengineered skin substitute or standard of care for treatment of chronic lower extremity diabetic ulcers.
    Zelen CM; Gould L; Serena TE; Carter MJ; Keller J; Li WW
    Int Wound J; 2015 Dec; 12(6):724-32. PubMed ID: 25424146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel treatment for venous leg ulcers.
    Alvarez OM; Fahey CB; Auletta MJ; Fernández-Obregón A
    J Foot Ankle Surg; 1998; 37(4):319-24. PubMed ID: 9710785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A bioengineered living cell construct activates an acute wound healing response in venous leg ulcers.
    Stone RC; Stojadinovic O; Rosa AM; Ramirez HA; Badiavas E; Blumenberg M; Tomic-Canic M
    Sci Transl Med; 2017 Jan; 9(371):. PubMed ID: 28053158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of a tissue engineered bilayered living skin analog, over meshed split-thickness autografts on the healing of excised burn wounds. The Apligraf Burn Study Group.
    Waymack P; Duff RG; Sabolinski M
    Burns; 2000 Nov; 26(7):609-19. PubMed ID: 10925183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of refractory, atypical lower extremity ulcers with tissue-engineered skin (Apligraf).
    Long RE; Falabella AF; Valencia I; Eaglstein WH; Kirsner RS
    Arch Dermatol; 2001 Dec; 137(12):1660-1. PubMed ID: 11735729
    [No Abstract]   [Full Text] [Related]  

  • 11. Experience with a new human skin equivalent for healing venous leg ulcers.
    Fahey C
    J Vasc Nurs; 1998 Mar; 16(1):11-5. PubMed ID: 9764027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An economic assessment of Apligraf (Graftskin) for the treatment of hard-to-heal venous leg ulcers.
    Schonfeld WH; Villa KF; Fastenau JM; Mazonson PD; Falanga V
    Wound Repair Regen; 2000; 8(4):251-7. PubMed ID: 11013015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Best-practice algorithms for the use of a bilayered living cell therapy (Apligraf) in the treatment of lower-extremity ulcers.
    Cavorsi J; Vicari F; Wirthlin DJ; Ennis W; Kirsner R; O'Connell SM; Steinberg J; Falanga V
    Wound Repair Regen; 2006; 14(2):102-9. PubMed ID: 16630097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apligraf living skin equivalent for healing venous and chronic wounds.
    Sibbald RG
    J Cutan Med Surg; 1998 Dec; 3 Suppl 1():S1-24-8. PubMed ID: 10082604
    [No Abstract]   [Full Text] [Related]  

  • 15. Skin grafting for venous leg ulcers.
    Jones JE; Nelson EA
    Cochrane Database Syst Rev; 2000; (2):CD001737. PubMed ID: 10796663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue engineered skin: Apligraf, a bi-layered living skin equivalent.
    Trent JF; Kirsner RS
    Int J Clin Pract; 1998 Sep; 52(6):408-13. PubMed ID: 9894378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Apligraf persistence and basement membrane restoration in donor site wounds: a pilot study.
    Hu S; Kirsner RS; Falanga V; Phillips T; Eaglstein WH
    Wound Repair Regen; 2006; 14(4):427-33. PubMed ID: 16939570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apligraf in the treatment of neuropathic diabetic foot ulcers.
    Edmonds M;
    Int J Low Extrem Wounds; 2009 Mar; 8(1):11-8. PubMed ID: 19189997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apligraf--a living human skin equivalent for the treatment of chronic wounds.
    Streit M; Braathen LR
    Int J Artif Organs; 2000 Dec; 23(12):831-3. PubMed ID: 11197742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of Apligraf in acute wounds.
    Kirsner RS
    J Dermatol; 1998 Dec; 25(12):805-11. PubMed ID: 9990773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.